Patent Eligibility Restoration Act Could Lead to Increased Costs for Critical Genetic Testing
Patent Eligibility Restoration Act Could Lead to Increased Costs for Critical Genetic Testing
Stay informed with expert insights, case studies, and tools to help your lab improve performance and make smarter revenue decisions.
Patent Eligibility Restoration Act Could Lead to Increased Costs for Critical Genetic Testing
The U.S. Centers for Medicare & Medicaid Services (CMS) revised the Clinical Laboratory Improvement Amendments of 1988...
Several medical organizations, including the College of American Pathologists and the American Medical Association,...
The U.S. House of Representatives Committee on Energy and Commerce held a hearing Thursday to discuss legislation...
The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (H.R. 5269/S.2761) was...
UPDATE: September 11, 2025
The College of American Pathologists (CAP) is urging the U.S. Department of Health and Human Services (HHS) to make...
The College of American Pathologists (CAP) is urging the U.S. Department of Commerce to exempt medical device products,...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as...
The Centers for Medicare & Medicaid Services (CMS) will now allow laboratories to bill the laboratory specimen...
The Centers for Medicare & Medicaid Services (CMS) announced the introduction of the Health Tech Ecosystem initiative...
Humana announced on July 22 that it would accelerate efforts to eliminate its prior authorization requirements.